Skip to Main Content

++

INTRODUCTION

++

olopatadine (nasal spray) (oh-loe-pat-ah-deen)

Patanase

Classification

Therapeutic: allergy, cold, and cough remedies

Pharmacologic: antihistamines

++
Indications
++

Relief of symptoms of allergic rhinitis.

++
Action
++

Antagonizes the effects of histamine at histamine1 receptor sites; does not bind to or inactivate histamine. Therapeutic Effects: Decreased symptoms of histamine excess, including rhinorrhea, sneezing, and nasal itching.

++
Adverse Reactions/Side Effects
++

CNS: drowsiness, headache. EENT: epistaxis, nasal perforation, nasal ulcerations, pharyngolaryngeal pain, postnasal drip. GI: bitter taste. Resp: cough.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Report signs of nasal or pharyngeal problems such as nosebleeds, nasal pain, ulceration, or increased postnasal drip.

++
Patient/Client-Related Instruction
++

  • Advise patient not to exceed the recommended dose or frequency of intranasal applications.

  • Advise patient to avoid alcohol and other CNS depressants because of the increased risk of sedation and adverse effects.

  • Instruct patient and family/caregivers to report other troublesome side effects such as severe or prolonged headache, drowsiness, cough, or bitter taste.

++
Pharmacokinetics
++

Absorption: 57% absorbed from nasal mucosa.

++

Distribution: Unknown.

++

Metabolism and Excretion: Minimal metabolism; 70% eliminated in urine mostly as unchanged drug; 17% fecal elimination.

++

Half-life: 8–12 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION

nasal

rapid

unknown

12 hr

++
Contraindications/Precautions
++

Contraindicated in: None noted.

++

Use Cautiously in: Nasal pathology other than allergic rhinitis; Geri: Dose cautiously in elderly patients; consider age-related decrease in organ function and concurrent medications; Lactation/OB: Use in pregnancy or lactation only when maternal benefit outweighs fetal risk; Pedi: Safe use in children <12 yr not established.

++
Interactions
++

Drug-Drug: ↑ CNS depression may occur with alcohol; avoid concurrent use.

++
Route/Dosage
++

Intranasal (Adults and Children ≥12 yr): 2 sprays in each nostril bid.

++
Availability
++

Nasal spray: 665 mcg/100 μL (0.6%) spray in 30.5-g bottle (provides 240 metered sprays).

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.